Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Roche

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review

The stock market rally revived with the major indexes reclaiming key levels and many top leaders flashing buy signals.

Investors Business Daily

If You Hate Getting Pap Smears, Here’s Some Extremely Good News

The first self-administered tests for collecting vaginal samples are on the way to health care facilities, making Pap smears more accessible and tolerable.

Inverse

From analysis to the latest developments in health,
read the most diverse news in one place.

The 10 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

Investors Business Daily

IBD 50 Stock TG Therapeutics Breaks Out Bullishly After 'Solid' Quarter

TG Therapeutics stock broke out Monday less than two weeks after the biotech company reported a surprise profit for the June quarter.

Investors Business Daily

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

Fortune

AstraZeneca Says It Has A 'Powerful' — And Differentiated — Approach To Obesity Treatment

AstraZeneca stock skidded Thursday despite strong quarterly sales as an FDA panel met to discuss its lung cancer treatment.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review

The stock market rally had some wild moves during the week. The Dow Jones and Russell 2000 jumped, but came off highs. The Nasdaq tumbled.

Investors Business Daily

Eli Lilly, Novo Nordisk — And Their Rivals — Skid On Roche's Weight-Loss Drug Results

Eli Lilly and Novo Nordisk fell Wednesday after Roche released positive early-stage trial data on its oral weight-loss drug.

Investors Business Daily

Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower

Eli Lilly stock seesawed Tuesday after a Food and Drug Administration panel endorsed its Alzheimer's treatment, donanemab.

Investors Business Daily

The Best European Stocks to Buy

European stocks are cheaper than their U.S. counterparts, and there are plenty of high-quality companies to choose from. Here's how you can find them.

Kiplinger

1st-of-its-kind Parkinson's treatment may slow aggressive disease, trial hints

A new antibody drug for Parkinson's disease appears to slow the progression of its movement-related symptoms, at least in some patients.

LiveScience

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

Investors Business Daily

Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space

There's a revolution in immunology that could completely shift a paradigm biotech stocks. And Big Pharma is paying billions to get in.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Top News

Revolutionary Antibiotic Breakthrough: Tackling Deadly Drug-Resistant Bacteria!

Researchers make strides in the battle against antibiotic resistance with a potential new class of drugs to combat drug-resistant bacteria, like CRAB.

Investors Business Daily

Roche Stock Rises On $3.1 Billion Deal For Obesity Drugmaker

Roche said it will spend up to $3.1 billion to acquire Carmot Therapeutics, a biotech firm developing obesity drugs.

The Conversation

Miniature organs on chips could revolutionize health-care research

To understand how bodies work, medical researchers and scientists have created mini models of organs, called organoids. This field of scientific research has had profound impacts on biological discovery and pharmaceutical development.

Investors Business Daily

Roche Follows Merck, Sanofi Into A Red-Hot Immunology Space With A $7.1 Billion Buyout

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Drug Giant Roche Skids As Covid Products Decline Weighs On Sales, Guidance

Roche stock skidded early Thursday after the Swiss drugmaker said declining demand for Covid products weighed on third-quarter sales.

The Guardian - UK

Patients in England will be first to access seven-minute cancer treatment jab

NHS is first health system to offer injection to hundreds of patients which will cut treatment times by up to three quarters

Investors Business Daily

Why Roche's Accidental Cancer Update Boosted Several Rivals By As Much As 22%

Roche accidentally published positive interim results from a lung cancer treatment study, which boosted shares of rivals Iteos and Arcus.

The Independent UK

Scottish firm working towards ‘transformative’ early blood test for Alzheimer’s

Scottish Brain Sciences is collaborating with Roche Diagnostics on the project.

Investors Business Daily

Sales Of TG Therapeutics' New Product Doubled — Here's Why Shares Halved

Sales of TG Therapeutics' highly anticipated multiple sclerosis drug, Briumvi, missed forecasts on Tuesday and TGTX stock plummeted.

The Guardian - UK

Pascal Soriot of AstraZeneca: ‘The climate crisis is a health crisis’

The man who led the drive to create a not-for-profit Covid vaccine is now focusing on the deaths caused by global heating and pollution

Investors Business Daily

Roche Could Take A Page Out Of Merck's Playbook. Why Roivant Surged.

Roche is in discussions to buy a stomach-disease treatment from Roivant for around $7 billion. The report sent ROIV stock surging Friday.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.